Stock Analysis

Croda International Full Year 2024 Earnings: EPS Misses Expectations

LSE:CRDA
Source: Shutterstock
Advertisement

Croda International (LON:CRDA) Full Year 2024 Results

Key Financial Results

  • Revenue: UK£1.63b (down 3.9% from FY 2023).
  • Net income: UK£158.5m (down 7.3% from FY 2023).
  • Profit margin: 9.7% (in line with FY 2023).
  • EPS: UK£1.14 (down from UK£1.23 in FY 2023).
revenue-and-expenses-breakdown
LSE:CRDA Revenue and Expenses Breakdown February 27th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Croda International EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.7%.

The primary driver behind last 12 months revenue was the Consumer Care segment contributing a total revenue of UK£920.0m (57% of total revenue). Notably, cost of sales worth UK£894.2m amounted to 55% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to UK£449.8m (78% of total expenses). Explore how CRDA's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 3.8% decline forecast for the Chemicals industry in the United Kingdom.

Performance of the British Chemicals industry.

The company's shares are up 4.4% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Croda International has 1 warning sign we think you should be aware of.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About LSE:CRDA

Croda International

Engages in the consumer care, life science, and industrial specialty businesses in in Europe, the Middle East, Africa, North America, Asia, and Latin America.

Flawless balance sheet with moderate growth potential.

Advertisement